'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues [0.03%]
监狱一次性服务模式的丙肝RNA检测项目及其相关问题
Chia-Yen Dai,Batbold Batsaikhan,Chung-Feng Huang
Chia-Yen Dai
Luciano Adorini,Michael Trauner
Luciano Adorini
The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed in the liver and intestine, regulates the expression of genes involved in cholesterol and bile acid homeostasis, hepatic gluconeogenesis, lipogenes...
Response to: Comment on 'End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB' [0.03%]
对《基于PEG-IFN治疗的慢性乙肝患者治疗结束时HBcrAg和HBsAb水平可识别持续功能性治愈》一文的回应
Di Wu,Da Huang,Weiming Yan et al.
Di Wu et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD [0.03%]
代谢功能异常性脂肪肝病（MASLD）的定义比MAFLD标准更适合于伴有NAFLD的消瘦患者
Arka De,Naveen Bhagat,Manu Mehta et al.
Arka De et al.
ChatGPT: The transformative influence of generative AI on science and healthcare [0.03%]
从科学到医疗保健：生成型AI的变革性影响——以ChatGPT为例
Julian Varghese,Julius Chapiro
Julian Varghese
In an age where technology is evolving at a sometimes incomprehensibly rapid pace, the liver community must adjust and learn to embrace breakthroughs with an open mind in order to benefit from potentially transformative influences on our sc...
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD [0.03%]
在NASH向MASLD转变的过程中不需要进行确证性生物标志物诊断研究
Vlad Ratziu,Jérôme Boursier;AFEF Group for the Study of Liver Fibrosis
Vlad Ratziu
Sherlot Juan Song,Jimmy Che-To Lai,Grace Lai-Hung Wong et al.
Sherlot Juan Song et al.
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection [0.03%]
RNai疗法RG6346治疗慢性乙型肝炎病毒感染首个人体随机研究
Edward J Gane,Won Kim,Tien Huey Lim et al.
Edward J Gane et al.
Background & aims: RG6346 is an N-acetyl-D-galactosamine (GalNAc)-conjugated, double-stranded RNA interference agent targeting the HBV genome S-region. We investigated the safety, tolerability, pharmacokinetics, and pharm...
Sara Reinartz Groba,Oliver Soehnlein
Sara Reinartz Groba
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US [0.03%]
美国住院肝硬化的患者急性肾损伤（包括肝肾综合征）的发病率和结局
Kavish R Patidar,Justin M Belcher,Kevin R Regner et al.
Kavish R Patidar et al.
Background & aims: Acute kidney injury (AKI) in cirrhosis is common and associated with high morbidity, but the incidence rates of different etiologies of AKI are not well described in the US. We compared incidence rates,...
Multicenter Study
Journal of hepatology. 2023 Dec;79(6):1408-1417. DOI:10.1016/j.jhep.2023.07.010 2023